MAR001: A Promising ANGPTL4 Inhibitor for Safe and Effective Lipid Lowering

Highlight

• MAR001, a novel ANGPTL4 inhibitory antibody, safely reduces triglycerides and remnant cholesterol by approximately 50% in early-phase clinical trials.
• Human genetic loss-of-function analyses show no adverse impact on mesenteric lymph node architecture or systemic inflammation, alleviating prior animal model safety concerns.
• Phase 1 and phase 1b/2a studies demonstrate good tolerability across healthy and metabolically impaired adults, supporting further therapeutic development.

Study Background and Disease Burden